To donate by check, phone, or other method, see our More Ways to Give page.

×
      LATEST NEWSOPINIONCLIMATEECONOMY POLITICS RIGHTS & JUSTICEWAR & PEACE
      LATEST NEWS
      OPINION

      alzheimer s

      Sen. Bernie Sanders speaks during rally against high drug prices

      Sanders Raises Fresh Concerns Over 'Outrageous' Price of New Alzheimer's Drug

      "Not only does the high price of Leqembi threaten Medicare's finances, it will also negatively impact seniors on fixed incomes suffering from Alzheimer’s who simply cannot afford to pay."

      Jake Johnson
      Jul 10, 2023

      Sen. Bernie Sanders on Monday reiterated his concerns over the staggering price tag of a newly approved Alzheimer's medication after the Biden administration failed to respond to his letter last month urging swift executive action to force down the cost.

      In a new letter to Health and Human Services Secretary Xavier Becerra, Sanders (I-Vt.) wrote that the current $26,500 list price for Leqembi is "outrageous" and demanded that the Biden administration explain "why the cost of this drug cannot be reduced to $8,900—which is the price independent experts believe it should cost based on its effectiveness."

      Keep ReadingShow Less
      News
      drug prices
      Bernie Sanders

      Sanders to Biden: Don't Let Big Pharma Bankrupt Medicare With 'Unconscionable' Price of Alzheimer's Drug

      "We must substantially lower the price that Medicare pays for prescription drugs like Leqembi," said the Vermont Independent, "and HHS has the power to do just that."

      Kenny Stancil
      Jun 07, 2023

      U.S. Sen. Bernie Sanders on Wednesday urged the Biden administration to use the "full extent" of its executive authority to lower the "outrageously high" price of a new Alzheimer's treatment being reviewed by federal regulators.

      "Alzheimer's is a horrible disease," Sanders (I-Vt.), chair of the Senate Health, Education, Labor, and Pensions (HELP) Committee, wrote in a letter to Xavier Becerra, secretary of the U.S. Department of Health and Human Services (HHS). "We must do everything possible to find a cure for the millions of people who suffer from it. But we cannot allow pharmaceutical companies to bankrupt Medicare and our federal government in the process."

      Keep ReadingShow Less
      News
      Big Pharma
      Rep. Carolyn Maloney and Rep. Frank Pallone

      House Dems Say FDA 'Inappropriately Collaborated' With Biogen on New Alzheimer's Drug

      "I am hopeful these findings are a wake-up call for FDA to reform its practices and a call to action to my congressional colleagues to continue oversight of the pharmaceutical industry to ensure they don't put profits over patients," said Rep. Carolyn Maloney.

      Brett Wilkins
      Dec 29, 2022

      Nearly two years after a leading U.S. consumer advocacy group sounded the alarm on the matter, House Democrats released a report Thursday showing the Food and Drug Administration and pharma giant Biogen "inappropriately collaborated" prior to the controversial approval of a new $28,000-per-year Alzheimer's drug of questionable efficacy.

      Originally carrying a $56,000 annual price tag for uninsured patients—which Biogen's then-CEO called "fair"—aducanumab, sold under the brand name Aduhelm, was approved by the FDA in June 2021. The approval came despite concerns that the drug—a monoclonal antibody treatment for patients with mild cognitive impairment caused by Alzheimer's—might not work, as well as safety trial data showing that a staggering 4 in 10 participants suffered potentially fatal brain bleeding and swelling after taking it.

      Keep ReadingShow Less
      News
      fda
      SIGN UP FOR OUR NEWSLETTER
      Quality journalism. Progressive values. Direct to your inbox.
      Follow Us
      Most Popular

      'Top Tier Trolling': Fetterman Gifts House GOP Case of Bud Light Over Biden Impeachment Hearing

      Senate Dems Want to Cancel All Student Lunch Debt—A 'Term So Absurd That It Shouldn't Even Exist'

      Supreme Court Could Trigger Hundreds of Billions in Corporate Tax Cuts 'With the Stroke of Pen'

      'Doesn't Make a Damn Bit of Difference': Trump Belittles UAW Strike in Speech at Nonunion Plant

      'Unbelievably Cruel': GOP Pushes Astronomical Cuts to Education, Housing, and Food Aid

      We Should Organize for a 20-Hour Work Week

      'He Cannot Be Trusted': Thomas Urged to Recuse From CFPB Case Over Koch Ties

      FCC Chair Confirms Plan to Reinstate Net Neutrality Rules Eviscerated Under Trump

      A Few Thoughts on This Admission: I Am Old

      Democratic Senators Sound Alarm Over Koch-Backed Plot to 'Eviscerate' Regulatory State

      Independent, nonprofit journalism needs your help.
      Please Pitch In
      Today!